💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dinoprostone

CHEMBL548 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
352.5 g/mol
LogP
2.8
Phase
4

A synthetic prostaglandin E2 used to ripen the cervix and induce labor in pregnant women at or near term. It acts on prostaglandin receptors to stimulate uterine contractions and soften the cervix. It is available as vaginal inserts, gels, and suppositories, and must be used in a monitored hospital setting due to the risk of uterine hyperstimulation.

Molekularmasse

352,5000 g/mol

LogP

2,80

TPSA

94,80 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Endometriosis Pain Management Asthma Chronic Obstructive Pulmonary Disease Migraine Obesity Lymphoma Type 2 Diabetes Hypertension Chronic Pain Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H32O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 5

                    

                    
                    

                        
Rotierbare Bindungen

                        
12

                    

                    
                    
                    

                        
Schwere Atome

                        
25

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A synthetic prostaglandin E2 used to ripen the cervix and induce labor in pregnant women at or near term. It acts on prostaglandin receptors to stimulate uterine contractions and soften the cervix. It is available as vaginal inserts, gels, and suppositories, and must be used in a monitored hospital setting due to the risk of uterine hyperstimulation.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Dinoprostone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL548.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5280360.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.